3' end formation of human type I and II collagen mRNAs
Project Number5R03AR052038-03
Contact PI/Project LeaderLUTZ, CAROL S
Awardee OrganizationUNIV OF MED/DENT OF NJ-NJ MEDICAL SCHOOL
Description
Abstract Text
DESCRIPTION (provided by applicant): We have a long-standing interest in how eukaryotic mRNA 3' ends are formed. Regulation of gene expression can be accomplished by regulating polyadenylation. We have combined this interest in polyadenylation with an interest in human collagen types I and II. Collagen plays a key role in normal cartilage development and skeletal morphogenesis. We have recently discovered and published that human COL1A2 polyadenylation is regulated by cis-acting elements present in the 3' untranslated region (3' UTR) of the COL1A2 mRNA, and that these elements influence the 3' end processing efficiency. Human COL1A1 and COL2A1 we have now discovered also contain these cis-acting elements. Based upon these findings, this project proposes to investigate the mechanism of regulation of polyadenylation of all these type I and II collagen pre-mRNAs. These investigations will expand our goal of better understanding the expression of collagens, and how mutations and abnormal gene expression regulation can initiate a disease state. Our specific aims for this project are: 1) To identify all the cis-acting elements involved in 3' polyadenylation site usage in the human collagen genes COL1A1, COL1A2, and COL2A1 and 2) To determine what trans-acting factor(s) bind to these cis-acting elements. First, we will identify cis-acting elements by deletion and site-directed mutagenesis, and examine their ability to affect polyadenylation efficiency both in vitro and in vivo. Second, protein factors that bind to these cis-acting signals will be explored and characterized. Determination of these protein factors will provide us with clues as to the functional significance of cis-acting auxiliary elements. Gaining an understanding of the RNA signals and protein factors involved in regulation of 3' end formation of these human collagen genes will help us to comprehend collagen gene expression regulation, which will in turn lead to novel insights into skeletal defects and other collagen-based diseases.
National Institute of Arthritis and Musculoskeletal and Skin Diseases
CFDA Code
846
DUNS Number
623946217
UEI
Project Start Date
15-January-2005
Project End Date
30-November-2008
Budget Start Date
01-December-2006
Budget End Date
30-November-2008
Project Funding Information for 2007
Total Funding
$73,721
Direct Costs
$47,409
Indirect Costs
$26,312
Year
Funding IC
FY Total Cost by IC
2007
National Institute of Arthritis and Musculoskeletal and Skin Diseases
$73,721
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5R03AR052038-03
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5R03AR052038-03
Patents
No Patents information available for 5R03AR052038-03
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5R03AR052038-03
Clinical Studies
No Clinical Studies information available for 5R03AR052038-03
News and More
Related News Releases
No news release information available for 5R03AR052038-03
History
No Historical information available for 5R03AR052038-03
Similar Projects
No Similar Projects information available for 5R03AR052038-03